Across all 3 studies, red grape supplementation showed beneficial effects on reducing aspartate aminotransferase (AST) levels, with predominantly small-to-moderate effect sizes. Doses ranged from 100–520 mg/day of grape seed extract over 28–60 days, with effects observed primarily in clinical populations with NAFLD or thalassemia. The evidence is promising but based on a small number of studies.
Caveats: Evidence base is small (only 3 studies) — conclusions should be considered preliminary. Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed). Effects are small in magnitude and clinical significance remains unclear.
The study aimed to investigate the iron-chelating, antioxidant, anti-inflammatory, and hepatoprotective activities of grape seed extract (GSE) supplement as well as its safety in β-thalassemia major (β-TM) pediatric patients receiving deferasirox as a standard iron-chelation therapy.
from: Grape seed extract in combination with deferasirox ameliorates iron overload, oxidative stFlavonoids intervention significantly decreased aspartate aminotransferase (AST)
GSE supplement significantly attenuated the serum levels of ... AST (p = 0.000)
insulin, HOMA-IR, TC, TG, LDL-c, ALT, AST, AST/ALT, SBP, DBP and MAP decreased and QUICKi and HDL-c increased significantly (p-value for all < 0.05)